课题基金 / 基金详情

Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential - r

Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential - r
新型 DHPS 抑制剂探索催化机制
批准号:
8679998
负责人:
Richard E. Lee
金额:
$38.72万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-01 至 2016-06-30

项目摘要

项目成果

Richard E. Lee的其他基金

相关文献

中文摘要
翻译
描述(由申请人提供):叶酸生物合成是一种基本的细菌途径,在高等动物中不存在,70多年来一直是抗菌剂的靶标。磺胺类药物通过作为对氨基苯甲酸(pABA)的非生产性底物类似物抑制途径中的二氢蝶酸合酶(DHPS)。然而,柔性的pABA结合位点在结构上易受耐药性突变的影响,并且磺胺类药物在治疗上迅速变得无效。相比之下,第二DHPS底物的结合位点,蝶呤-焦磷酸,被埋在一个保守的口袋,是不太可能容忍突变。我们建议产生新的有效的DHPS抑制剂,专门从事这个口袋。这些抑制剂可以潜在地开发成仍然靶向叶酸合成但避免耐药性问题的新型治疗剂。 为了产生任何酶的有效抑制剂,了解其活性位点的结构和机制至关重要。DHPS基本上没有这些信息,了解DHPS如何在分子水平上进行催化将是该提案的中心目标。另一个目标将是了解磺胺类药物耐药性的分子和功能基础,以避免我们未来的药物设计中出现这个问题。这种综合方法将需要两名主要研究人员在结构生物学、药物化学、生物化学、计算生物学和微生物学方面的共同专长。该项目还将结合相对较新的基于片段的药物发现技术,以确定可以通过化学合成容易地制备的新型小抑制性化学支架。申请中描述的令人兴奋的新数据为该项目实现其最终目标提供了强有力的支持,即快速开发新的抗菌剂,最大限度地减少耐药性的出现。虽然我们的目标是开发广谱抗感染药物,我们的微生物筛选将集中在S。金黄色葡萄球菌和Jirovecii,近年来在美国已经成为特别有问题的传染病病原体。
英文摘要
DESCRIPTION (provided by applicant): Folate biosynthesis is an essential bacterial pathway that is absent in higher animals, and it has been a target of antibacterial agents for over 70 years. Sulfa drugs inhibit the enzyme dihydropteroate synthase (DHPS) in the pathway by acting as non-productive substrate analogs of p-aminobenzoic acid (pABA). However, the flexible pABA binding site is structurally susceptible to resistance mutations, and the sulfa drugs are rapidly becoming therapeutically ineffective. In contrast, the binding site of the second DHPS substrate, pterin-pyrophosphate, is buried in a conserved pocket that is less likely to tolerate mutations. We propose to generate new classes of potent DHPS inhibitors that specifically engage this pocket. These inhibitors can potentially be developed into novel therapeutic agents that still target folate synthesis but which avoid the problems of resistance. To generate effective inhibitors of any enzyme, it is crucial to understand the structure and mechanism of its active site. This information is largely absent for DHPS, and understanding how DHPS performs catalysis at the molecular level will be a central goal of the proposal. Another goal will be to understand the molecular and functional basis of sulfa drug resistance to avoid this problem in our future drug designs. This comprehensive approach will require the joint expertise of the two principal investigators in structural biology, medicinal chemistry, biochemistry, computational biology and microbiology. The project will also incorporate the relatively new technique of fragment based drug discovery to identify novel small inhibitory chemical scaffolds that can readily be elaborated by chemical synthesis. Exciting new data described in the application provide strong support that the project can realize its ultimate goal which is to rapidly develop new antimicrobials that minimize the emergence of drug resistance. Although we aim to develop broad-spectrum anti-infective agents, our microbiological screening will focus on S. aureus and P. jirovecii that have emerged as particularly problematical infectious disease agents in the U.S. in recent years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Spectinomycin analogs for NTM infections
Spectinomycin analogs for NTM infections
Spectinomycin analogs for NTM infections
Training in the Design and Development of Infectious Disease Therapeutics